Neuronetics, Inc. (NASDAQ:STIM – Get Free Report) major shareholder Jorey Chernett sold 706,840 shares of Neuronetics stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $1.43, for a total transaction of $1,010,781.20. Following the completion of the sale, the insider owned 9,512,628 shares of the company’s stock, valued at $13,603,058.04. This trade represents a 6.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Jorey Chernett also recently made the following trade(s):
- On Friday, November 6th, Jorey Chernett sold 250,804 shares of Neuronetics stock. The shares were sold at an average price of $2.39, for a total transaction of $599,421.56.
- On Friday, November 13th, Jorey Chernett sold 2,187,051 shares of Neuronetics stock. The shares were sold at an average price of $1.15, for a total transaction of $2,515,108.65.
- On Wednesday, November 11th, Jorey Chernett sold 86,757 shares of Neuronetics stock. The stock was sold at an average price of $1.61, for a total transaction of $139,678.77.
- On Monday, November 9th, Jorey Chernett sold 103,959 shares of Neuronetics stock. The stock was sold at an average price of $2.06, for a total transaction of $214,155.54.
- On Monday, November 9th, Jorey Chernett bought 40,000 shares of Neuronetics stock. The shares were acquired at an average cost of $1.99 per share, for a total transaction of $79,600.00.
- On Friday, October 30th, Jorey Chernett purchased 18,000 shares of Neuronetics stock. The stock was acquired at an average price of $2.27 per share, with a total value of $40,860.00.
Neuronetics Price Performance
NASDAQ STIM opened at $1.39 on Monday. The company has a current ratio of 2.01, a quick ratio of 1.82 and a debt-to-equity ratio of 2.76. Neuronetics, Inc. has a 1-year low of $0.80 and a 1-year high of $3.44. The company has a 50 day moving average of $2.35 and a 200-day moving average of $1.87. The company has a market cap of $108.04 million, a price-to-earnings ratio of -4.21 and a beta of 1.36.
Neuronetics News Roundup
These are some of the STIM news items that stood out recently:
- Positive Sentiment: Third-quarter revenue was $41.96 million, above the $40.43 million analyst estimate, while its $0.02-per-share loss was narrower than the expected $0.09 loss. The results may support sentiment about improving performance. Article: Neuronetics stock: Q3 revenue rises as loss narrows
- Negative Sentiment: Major shareholder Jorey Chernett disclosed several sales from November 6–13, totaling about 3.34 million shares, partly offset by a 40,000-share purchase. After the latest sale, Chernett held about 7.33 million shares. The scale of the selling may raise concerns about near-term supply and investor confidence. SEC filing on Chernett’s transactions
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in STIM. Madryn Asset Management LP bought a new position in shares of Neuronetics in the 2nd quarter valued at $24,102,634. BlackRock Inc. acquired a new position in shares of Neuronetics during the 2nd quarter worth $776,000. FourWorld Capital Management LLC raised its holdings in shares of Neuronetics by 59.9% during the 1st quarter. FourWorld Capital Management LLC now owns 1,489,322 shares of the company’s stock worth $2,160,000 after buying an additional 558,072 shares in the last quarter. ADAR1 Capital Management LLC bought a new stake in shares of Neuronetics during the 2nd quarter worth $130,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Neuronetics during the 2nd quarter worth $50,000. 53.59% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on STIM. B. Riley Financial increased their target price on Neuronetics from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Friday, November 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neuronetics in a research note on Monday, September 14th. Citigroup reaffirmed a “market outperform” rating on shares of Neuronetics in a research report on Tuesday, July 21st. Finally, BTIG Research reaffirmed a “buy” rating and set a $6.00 price objective on shares of Neuronetics in a research report on Thursday, September 17th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $5.00.
Read Our Latest Analysis on STIM
Neuronetics Company Profile
Neuronetics, Inc. is a medical technology company that develops and commercializes noninvasive treatments for certain mental health conditions. Its flagship product is the NeuroStar Advanced Therapy System, which uses transcranial magnetic stimulation to deliver targeted magnetic pulses to areas of the brain. NeuroStar is FDA-cleared for treating major depressive disorder in adults who have not achieved satisfactory improvement with antidepressant medication. The company also provides treatment-related services and support for clinicians and patients.
Featured Articles
- Five stocks we like better than Neuronetics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.
